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focused on volume definition to be held before dose-
planning. To improve quality thresholds can be tighten and a 
goal for next year is to reduce the time for curative patients 
to 12 days and to palliative patients to 3. 
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Purpose/Objective: The aim of the study is to develop 
proper quality indexes to increase the control on the 
workflow in radiotherapy by a quantitative analysis of data 
extracted from the R&V system database of our radiotherapy 
department 
Materials and Methods: Several technical parameters related 
to delivery modality (3D CRT or VMAT), use of flattened (FF) 
or unflattened (FFF) beams, pre treatment imaging and other 
planning details were extracted for each patient by proper 
SQL querying of the database. These features were analyzed 
to derive indicators for radiotherapy treatment quality and 
workflow monitoring. Introduction of new clinical protocols 
of hypofrationated treatments was quantified by considering 
the incidence of standard fraction doses up to 3 Gy per 
fraction against higher fractionation schemes. Couch shifts 
between laser-based patient positioning and IGRT setup were 
evaluated for all IMRT/VMAT hypofractionated breast 
treatments as a tool to sistematically take isocenter accuracy 
under control 
Results: Data since 2003 show an increasing average trend in 
the number of new patients treated per year at our centre 
(up to 2500 in 2013). Data show a significant increment of 
technological innovation starting from 2010 when IMRT 
(mostly rapidarc) have been introduced. The fraction of 
rapidarc treatments was about 20% in 2010 up to a proportion 
of about 75% at the end of 2013. Since 2010, average 
treatment Beam On Time (BOT) resulted in a significant 
decrease for high fraction doses up to a value of about 2 
minutes found in 2013 for every treatment, regardless the 
adopted fractionation and technique (Fig 1A). This result was 
achieved due to the availability of FFF high dose rate beams 
in linear accelerators (presently used in about 90% of cases 
for fraction doses above 4Gy) coupled with use of the VMAT 
technique available since 2010 in our centre. In the last 5 
years, use of hypofractionation has grown from 16% to about 
40% of treatments(Fig 1B). The incidence of pre treatment 
imaging was evaluated as a workflow indicator for treatments 
on all machines and patients: data for 2013 showed that IGRT 
was applied to more than 80% of treatments in all therapy 
sessions and always performed in the first fraction for all 
patients. Evaluation of couch shifts for complex breast 
treatments was found to be on average below 5 mm as vector 
modulus. 
 
 
Fig1 A) Average BOT according to different fractionations B) 
fractionation over time 
 
Conclusions: The evolution of technology in a radiotherapy 
department was quantified and evaluated by means of a data 
mining of treatment records since 2003.The introduction of 
new protocols coupled to a growing complexity of treatments 
led to higher doses per fraction without increasing BOT for a 
better patient overall comfort. The evaluation of patient 
positioning and IGRT monitoring using our indicators was 
found to be suitable to obtain high quality standards in 
essential parts of the radiotherapy workflow in our center. 
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Purpose/Objective: Radiotherapy is indicated in at least 48% 
of cancer treatments1,4 and is recognised as an extremely 
cost-effective treatment option for low and middle income 
countries4. And yet of 139 LMIC countries 55 have no access 
to RT at all, and 80 have only minimal treatment facilities 
available6. It has been recognised by the IAEA5 that the high 
capital cost and complex technological delivery of 
conventional X-ray radiotherapy systems is a major barrier 
preventing an estimated 4 million cancer sufferers worldwide 
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from receiving best practice treatment every year3. Our 
vision for Nano-X is to provide a cost-effective solution for 
radiotherapy treatment by moving much of the complexity 
from the hardware to the software. Our aim is to produce a 
commercially viable system within three years. 
Materials and Methods: The Nano-X collaboration has utilised 
patient rotation technology to significantly reduce the 
complexity, and thus cost, of radiotherapy. Patient rotation 
technology allows the patient to be mechanically moved 
during treatment, in contrast to a conventional device which 
moves the linac, typically weighing about 3T, around a fixed 
patient position. This allows the use of a static linac and thus 
also reduces the size and cost of the bunker. The Nano-X 
includes a 6MV linac with MLC, MV panel and a novel kV cone-
beam imaging system. The integrated imaging systems allow 
for real-time and adaptive image guided therapy which will 
alleviate the requirements of pre-treatment patient 
alignment reducing the on-site staffing burden. 
Results: The Nano-X prototype is currently under 
construction by LinaTech Medical Technologies Ltd and is due 
for completion and installation at Nelune Comprehensive 
Cancer Centre (NCCC) in 2015, with a planned commercial 
product available in 3 years. The initial estimated cost of a 
commercial Nano-X is around 10% of the cost of a 
conventional RT machine, with bunker costs reduced by up to 
67%2. 
Conclusions: With the low-cost and design that is specifically 
tailored towards LIMCs as well as rural and remote regions 
the Nano-X represents a solution to RT availability 
worldwide. The Nano-X prototype is currently under 
construction and will be installed at NCCC in 2015. 
Discussions are underway to determine the first LMIC 
treatment site. 
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Purpose/Objective: Alterations in metabolism seem to 
influence initiation of malignancy as well as recurrence. 
However the effect of diabetes, as one of the most common 
endocrine disorders, and metformin therapy on glioblastoma 
(GBM), remain understudied. Our aim is to examine the 
influence of diabetes and metformin on progression and 
survival in GBM patients.  
Materials and Methods: 270 patients with primary 
glioblastoma underwent radiation therapy between 2007 and 
2011 at the XXX. We assessed clinical records as well as 
pretherapeutic and follow up MR-imaging. 33 patients (12.2 
%) were identified with a pretherapeutic history of diabetes, 
treated with metformin in 14 cases (42.4 %). Survival and 
correlations were calculated using the t-test, log-rank 
analysis and univariate cox proportional hazards ratio. 
Results: Diabetes was associated with significant decreased 
overall survival rates (p = .047) in GBM patients in the 
prognostic favorable subgroup without corticosteroid 
therapy. Furthermore persistent mild - (p < .001) and 
persistent excessive hyperglycemia (p < .001) correlated with 
decreased survival. Interestingly, diabetic patients with 
metformin therapy showed a prolonged progression-free 
interval (p = .037). Recurrence patterns were not affected by 
diabetes or metformin therapy. 
Conclusions: We could show an adverse relationship between 
diabetes and survival in GBM patients. Furthermore our 
clinical findings suggest that metformin therapy prolongs the 
progression-free survival in GBM patients with diabetes. 
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Purpose/Objective: The prognosis in patients with high grade 
glioma remains poor, and the use of dose escalation beyond 
60 Gy using three-dimensional conformal radiotherapy (RT) or 
intensity-modulated radiotherapy (IMRT) has not lead to a 
survival benefit. Previous experimental and clinical studies 
indicated that hyperbaric oxygen (HBO) therapy could 
enhance an antitumor effect of RT. A few clinical studies 
indicated that HBO therapy immediately before conventional 
RT was safe and seemed to be effective in patients with high 
grade glioma. We conducted the combination therapy of 
chemoradiotherapy (CRT) using IMRT boosts in combination 
with HBO therapy. The purpose of this study was to evaluate 
the feasibility and efficacy of the combination therapy.  
